Royalty Pharma plc
RPRX
Pozycja w akcjach
#895
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a... Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Cena akcji
$60.39
Kapitalizacja rynkowa
$26.89B
Zmiana (1 dzień)
-0.93%
Zmiana (1 rok)
63.17%
Kraj
US
Handel Royalty Pharma plc (RPRX)
Kategoria
Healthcare
EPS dla Royalty Pharma plc (RPRX)
EPS na dzień June 2026 TTM: $2.41
Według najnowszych raportów finansowych i ceny akcji firmy Royalty Pharma plc, obecny EPS (TTM) wynosi $2.41. Na koniec roku 2024 firma miała EPS w wysokości $1.92, spadek w porównaniu do do EPS z roku 2023, który wynosił $2.54.
Historia EPS dla Royalty Pharma plc od 2015 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $2.41 | 34.64% |
| 2025 | $1.79 | -6.61% |
| 2024 | $1.92 | -24.41% |
| 2023 | $2.54 | 2,492.43% |
| 2022 | $0.10 | -93.45% |
| 2021 | $1.49 | -42.47% |
| 2020 | $2.60 | -59.54% |
| 2019 | $6.42 | 182.80% |
| 2018 | $2.27 | 13.86% |
| 2017 | $1.99 | 113.83% |
| 2016 | $0.93 | -2.67% |
| 2015 | $0.96 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.52 | -78.42% |
US
|
|
| $0.02 | -99.22% |
HK
|
